Xeris Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xeris Biopharma Holdings, Inc. (XERS) on June 10, 2026. The filing discloses a material event regarding the restructuring of the Company's debt obligations through privately negotiated exchange agreements.
Key Financial Metrics and Transaction Details
- Debt Restructuring: The Company entered into agreements to exchange approximately $23 million in aggregate principal amount of its 8.00% Convertible Senior Notes due 2028 (the "2028 Notes").
- Exchange Consideration: Noteholders will receive a combination of cash (equal to the principal amount) and shares of common stock. The share portion is based on the volume-weighted average price over a 21-day period starting June 11, 2026.
- Remaining Debt: Following the exchange, approximately $10.5 million in aggregate principal amount of the 2028 Notes will remain outstanding.
- Liquidity Impact: The Company intends to fund the cash portion of the exchange using liquidity on-hand.
- Transaction Scope: The notes being exchanged represent approximately 69% of the total outstanding principal of the 2028 Notes.
Material Changes and Outlook
The primary material change is the significant reduction in outstanding convertible debt, reducing the principal balance by roughly two-thirds. The closing of the exchange is expected to occur on or about July 15, 2026, subject to customary closing conditions. The shares issued in this transaction will be unregistered and issued in a private placement to institutional accredited investors and qualified institutional buyers.
Risks and Contingencies
The filing includes standard forward-looking statements regarding the expected timing of the exchange and the determination of the share portion of the consideration. Actual results may differ materially due to market conditions and other uncertainties. The Company does not undertake an obligation to update these statements.
Investor Verification Checklist
- Verify the final closing date of the exchange (expected July 15, 2026) and confirm the transaction has been completed.
- Monitor the volume-weighted average price of XERS stock during the 21-day averaging period to estimate the dilution impact from the share portion of the exchange.
- Review subsequent filings to confirm the exact number of shares issued and the final reduction in the 2028 Notes principal balance.
- Assess the impact of the cash outflow on the Company's remaining liquidity and runway.